The Senate Health, Education, Labor & Pensions Committee last night voted 13-9 to advance legislation that would reauthorize Food and Drug Administration user fee programs and modify the regulatory framework for laboratory developed tests. AHA last week urged lawmakers to consider certain changes to the LDT provisions to ensure continued access to these critical tests.  
 
The House last week passed its own bill (H.R. 7667) to reauthorize FDA user fee programs, which does not include the LDT provisions. Among other provisions, the House bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies. 
 

Related News Articles

Headline
The House is expected to begin a final vote Nov. 12 on the Senate-backed funding package, bringing a potential end to the government shutdown one step closer.…
Headline
The Senate Nov. 10 passed legislation to fund the federal government that will now head to the House for a vote as early as the evening of Nov. 12, as an end…
Headline
The Senate Nov. 9 took a critical first step toward ending the government shutdown as seven Democrats and Sen. Angus King, I-Maine, joined Republicans to…
Headline
Senate negotiations on a potential funding deal to end the record-long government shutdown are ongoing, and the chamber is likely to continue working through…
Headline
The AHA expressed support Nov. 3 for the bipartisan Home Health Stabilization Act (H.R. 5142), legislation that would establish a two-year pause on planned…
Chairperson's File
Public
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…